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from the DCE with and without out-out differed. Results suggest that including 
an opt-out reduces efficiency with respect to power.  
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OBJECTIVES: To empirically test to what extent the layout of choice tasks (i.e., 
displayed in words or graphics) in a Discrete Choice Experiment (DCE) influences 
the attribute estimates and the conclusions drawn from the DCE. METHODS: A 
DCE questionnaire was sent to the parents of 2500 newborn babies aged 6 weeks 
at maximum. Each questionnaire contained two times the same 9 choice tasks, 
ones words were used to describe the attributes and levels and ones graphics 
were used. The DCE consisted of five attributes related to the decision of parents 
to vaccinate their newborn baby against the rotavirus (vaccine effectiveness, 
frequency of severe side effects, protection duration, location, costs). Mixed logit 
models were conducted to estimate the relative importance of the attributes. 
RESULTS: Preliminary results are based on 279 observations from 31 parents. In 
February 2013 data collection will be completed and analyzed. When comparing 
the choices of every respondent per choice tasks, 58% chose inconsistent at 1 or 
more choice tasks and 35% chose inconsistent in two or more choice tasks. In 
both datasets (layout in words and graphics), vaccine effectiveness (βeffects code 
1=0.64 and βeffects code 1=1.00, βeffects code 2=0.67 and βeffects code 2=0.01), frequency of severe 
side effects (βeffects code 1=0.26 and βeffects code 1=0.41, βeffects code 2=1.22 and βeffects code 
2=0.89) protection duration (β=0.37, β=0.17) and costs (β=-0.10, β=-0.11) showed 
significant attribute estimates (P<.05). However, the relative importance of these 
attributes differed between both datasets. CONCLUSIONS: For now it can be 
concluded that the presentation of the choice sets (by either using words or 
graphics) in a DCE influences study outcomes. Besides extensive pilot testing to 
ensure the choice tasks are understood and interpreted as intended, it might be 
worthwhile to include discussions about the layout of the choice tasks in the 
focus group stage of the DCE designing process.  
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EVALUATING AND IMPROVING METHODS FOR COGNITIVE DEBRIEFING PRO 
QUESTIONNAIRES  
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Adelphi Values, Boston, MA, USA  
OBJECTIVES: Cognitive debriefing is critical to the content validity of patient-
reported outcome (PRO) questionnaires. The goal of this poster is to evaluate the 
time needed to adequately debrief PRO questionnaires and to generate a set of 
questions that could facilitate the timely and successful completion of cognitive 
debriefing interviews. METHODS: To evaluate cognitive debriefing methods, two 
research activities were conducted. First, a time-to-complete analysis was 
conducted using n=44 audio-recorded patient interviews to understand how 
much time was required to debrief single PRO items. Next, select studies (n=15) 
were reviewed to document the researcher stated objectives of their cognitive 
debriefing activities. This list of objectives was used to inform a set of questions 
that could be asked of patients during debriefing to accomplish those objectives. 
RESULTS: The time-to-complete analysis showed that single questionnaire items 
required approximately 5 minutes and 45 seconds to be fully debriefed. Primary 
objectives of cognitive debriefing interviews included the evaluation of a) 
patients’ interpretation of the instructions, items, and response options relative 
to questionnaire developer’s intentions; b) the extent to which item concepts 
assessed in the questionnaire are comprehensive to the general concept of 
measurement; c) item language that reflects patient experience, and d) response 
options as representative of patient health status. CONCLUSIONS: Results 
suggest that it takes approximately 60 minutes to fully debrief a PRO 
questionnaire constructed of 10 items. Though longer interviews are possible, 
interviews lasting longer than 60 minutes may produce data of poor quality due 
to patient fatigue. Therefore, debriefing studies require clearly stated objectives 
along with targeted questions to help the interviewer successfully and efficiently 
meet those objectives. The interview questions discussed in this poster can be 
used by researchers to facilitate the timely and targeted completion of cognitive 
debriefing interviews for the purpose of supporting content validity of a PRO 
questionnaire.  
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OBJECTIVES: Prescription cost-sharing and pill burden may predict duration of 
persistence with antiretroviral therapy (ART) in HIV patients. These predictors 
are correlated and may vary with time, necessitating sophisticated modeling 
approaches to generate unbiased and consistent estimates of their effects on 
ART persistence. This analysis compared the estimated effect of ART cost-
sharing on ART persistence when adjusting for ART pill burden through 
traditional time-dependent Cox versus newer marginal structural modeling 
(MSM) approaches. METHODS: Retrospective observational cohort study using a 
large U.S. claims database. Subjects were commercially-insured antiretroviral-
naïve HIV patients initiating ART during the period January 1, 2003 to December 
31, 2007. ART persistence was measured as the number of days from ART 
initiation until addition of a new antiretroviral, 30-day gap in possession of an 
initiated antiretroviral, or censoring at loss to follow-up. During the period of 
persistence, ART cost-sharing per 30-day supply of the ART regimen and daily 
average ART pill burden were measured within a patient-quarter repeated-
measures panel dataset. Time-dependent Cox and MSM approaches were 
compared with respect to their estimated effect of ART cost-sharing (>$50 versus 
≤$50) on ART persistence. MSM was implemented using inverse probability of 
treatment weights within a weighted Cox model with generalized estimating 
equations. RESULTS: Sample comprised 3,731 patients producing 19,199 patient-
quarters: mean age=41.1 years; male=83.2%; median ART cost-sharing=$40; 
median ART pill burden=3.2. Using time-dependent Cox modeling, ART cost-
sharing >$50 (versus ≤$50) was estimated to be not significantly associated with 
ART persistence (Hazard Ratio [HR]=0.96, 95% confidence interval [CI]=0.78-1.18, 
p=0.733). In contrast, using MSM, ART cost-sharing >$50 was estimated to be 
significantly associated with shorter durations of ART persistence (HR=1.28, 95% 
CI=1.16-1.43, p<0.001). CONCLUSIONS: Appropriate model choice is critical in the 
presence of complex relationships between correlated time-varying predictors 
and outcomes. Using MSM, ART cost-sharing >$50 was found to be significantly 
associated with shorter durations of ART persistence.  
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EFFICIENCY OF DIALYSIS CENTERS IN THE UNITED STATES: AN UPDATED 
EXAMINATION OF FACILITY CHARACTERISTICS THAT INFLUENCE 
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OBJECTIVES: Medicare has announced plans to include efficiency measures in 
the End-Stage Renal Disease Quality Incentive Program. Few studies have 
analyzed US dialysis center efficiency, despite ongoing payment incentives to 
deliver dialysis care more cost-effectively. The objective of this study was to 
assess overall dialysis center efficiency as well as the impact of anemia drug 
choice on efficiency. METHODS: Using 2010 data from Medicare Renal Cost 
Reports, a data envelopment analysis (DEA) was performed to model the 
technical efficiency of 4,343 free-standing dialysis centers. DEA uses a linear 
programming technique that converts multiple inputs (costs, staffing levels) and 
an output measure (number of dialysis sessions) to a relative efficiency score 
between 0 and 1, where scores are proportional to the efficiency frontier (score of 
1.0.) A second DEA was conducted to assess changes in score distribution if labor 
and supply cost inputs were reduced due to switching to less frequent dosing of 
anemia drugs. Regression analysis was performed to account for variations in 
organizational and environmental conditions. RESULTS: About 78% of facilities 
were owned by the two largest chains. Nearly 93% of facilities were for-profit; 
75% were in urban areas. 33% of facilities were functioning efficiently (efficiency 
scores ≥.90); 30% had scores between .70 and .90, and 37% scored <.70. Neither 
the intensity of market competition nor the profit status of the facility had a 
significant effect on efficiency. Facilities that were members of large chains were 
less likely to be efficient. Cost and labor savings due to changes in drug protocols 
had little effect on overall dialysis center efficiency. CONCLUSIONS: 
Opportunities exist for continued improvements in the efficiency of US dialysis 
facilities. DEA may be a useful tool for evaluating dialysis center efficiency. 
Future studies should incorporate quality of care dimensions and case-mix 
adjustment in the measurement of efficiency.  
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A SYSTEMATIC REVIEW OF THE NETWORK META-ANALYSIS LITERATURE  
Chambers JD, Pyo J, Winn A, Neumann PJ 
Tufts Medical Center, Boston, MA, USA  
OBJECTIVES: Network meta-analysis is a relatively new statistical approach for 
synthesizing evidence. Network meta-analysis includes both ‘‘direct’’ and 
‘‘indirect’’ comparisons to strengthen inference concerning the relative efficacies 
of treatment pairs. Further, the approach facilitates simultaneous inference 
regarding all treatments, allowing the ranking of therapeutic options by 
effectiveness. This study reviewed published network meta-analyses pertaining 
to pharmaceuticals, and identified trends in the literature. METHODS: Using the 
PubMed electronic database, we performed a systematic search using the 
following terms; “network meta-analysis”, “mixed treatment comparison”, and 
“indirect treatment comparison”. Two reviewers assessed each study. We 
excluded studies that did not include pharmaceuticals or biologics, pertained to 
methods, did not report efficacy endpoints, or were not published in English. For 
each study we reported publication year, funding source (industry or non-
industry), disease type, and whether the study included a biologic treatment. 
RESULTS: A total of 142 of the 288 abstracts identified through the systematic 
search were included. Over time, there has been a rapid growth in the literature, 
with nine studies published between 1997 and 2008, 14 in 2009, 18 in 2010, 38 in 
2011, and 63 in 2012. The majority of studies were non-industry funded (55.6%). 
Drugs for musculoskeletal and rheumatic disease were the most frequently 
evaluated (22.5%), followed by drugs for cardiovascular disease (14.8%), cancer 
(11.3%), e.g., breast cancer and lung cancer, and infectious disease (11.3%), and 
psychiatric and neurological conditions (10.5%). A total of 35.9% of studies 
included at least one biologic. CONCLUSIONS: The number of published network 
meta-analyses is growing rapidly. Studies are performed across a range of 
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disease areas and therapeutic classes, but treatments for musculoskeletal and 
rheumatic disease are evaluated most frequently.  
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EXTENSION OF THE HOSMER-LEMESHOW GOODNESS OF FIT STATISTIC TO 
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1Quintiles Outcome, Rockville, MD, USA, 2Quintiles Outcome, Cambridge, MA, USA  
OBJECTIVES: Studies of health outcomes commonly involve binary measures, 
assessed multiple times. Although generalized linear mixed (GLIMMIX) models 
are well suited for analyzing these data, there does not exist a formal statistic to 
assess the goodness of fit (GOF) for GLIMMIX models. We developed an extension 
of the Hosmer-Lemeshow GOF test used for logistic regression that can be 
applied to GLIMMIX models. METHODS: The correlation among repeated 
measurements of the binary outcome variable was accounted for by a random 
effect in the GLIMMIX model. The principles of Hosmer-Lemeshow method were 
followed. The linear unbiased estimate of dependent variables were transformed 
to the original probability, sorted from least to largest, and divided into deciles. A 
Chi-square statistic and corresponding p-value with eight degrees of freedom, 
was calculated based upon the expected and observed numbers among deciles. 
The proposed GOF test was validated by a simulation study with 1000 runs 
generated from logistic regression models with and without random effects. The 
results were compared with the Hosmer-Lemeshow GOF test in situations where 
the latter is appropriate. The proposed method was used in the analysis of a 
comparative effectiveness (CE) study of ophthalmologic treatments for open-
angle glaucoma patients. RESULTS: When there was no random effect, the 
proposed GOF test results from the GLIMMIX procedure were almost identical to 
those of Hosmer-Lemeshow GOF test from the logistic procedure. With a random 
effect built in a correctly specified model, the goodness of fit rejection rate was 
5.1%, which is close to the nominal level 5%. The proposed test did not indicate 
lack of fit for the regression models in the CE study. CONCLUSIONS: The 
proposed GOF test provides an assessment of model fit for models with binary 
outcomes and repeated measurements for predictor variables.  
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ANNUAL HEALTH CARE CHARGES AND UTILIZATION IN ATRIAL FIBRILLATION 
(AF) PATIENTS ON DRONEDARONE COMPARED TO AMIODARONE  
Dahal A, Marrouche N, Ghate SR 
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OBJECTIVES: Amiodarone, a frequently used drug for AF patients, has been 
associated with severe adverse events. A relatively new drug, dronedarone, has 
been shown to reduce the risk of adverse events and duration of hospital stays in 
AF patients. The objective of this study was to assess the annual health care 
charges and utilization in AF patients on dronedarone compared to amiodarone. 
METHODS: Data from the University of Utah Enterprise Data Warehouse were 
analyzed for AF patients from October 2009 to October 2012. Eligible patients had 
a prescription for either amiodarone or dronedarone on index date; had 6 
months pre-index and 12 months post-index follow-up activity. Annual total 
charges and annual inpatient and outpatient visits were assessed during the 
follow-up period. Generalized linear model (GLM) with gamma distribution and 
log link and negative binomial model (NBM) were used to examine the annual 
charges and usage between the two groups, respectively, controlling for 
demographics, insurance status, baseline comorbidities, and prior drug use. 
RESULTS: Of the 1003 patients analyzed, 134 (13.4%) patients were prescribed 
dronedarone and 869 (86.6%) were prescribed amiodarone. The age and gender 
distribution was not significantly different between the two groups (p>0.05). The 
mean unadjusted annual health care charges for dronedarone were significantly 
lower compared to amiodarone ($40,395 vs. $96,387, p<0.05). The mean annual 
outpatient visits for dronedarone were significantly higher compared to 
amiodarone (7.96 vs. 4.78, p<0.05). GLM results indicate that dronedarone 
patients had 71% lower annual health care charges compared to amiodarone 
patients (coeff. -0.711, p<0.05). NBM results show that dronedarone patients were 
61% less likely to have inpatient visits (coeff. -0.61, p<0.05) and 39% more likely 
to have outpatient visits (coeff. 0.39, p<0.05) compared to amiodarone patients. 
CONCLUSIONS: The annual health care charges and inpatient visits were 
significantly lower but outpatient utilization was higher in dronedarone 
compared to amiodarone patients.  
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USING PARAMETRIC SURVIVAL CURVES TO ESTIMATE PROGRESSION FREE 
SURVIVAL IN A NETOWRK META-ANALYIS OF TREATMENTS FOR CHRONIC 
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OBJECTIVES: When comparing survival time among competing treatments, the 
assumption of constant hazards, necessary for use of semi-parametric modeling 
techniques, cannot always be met. Use of a fully parametric model provides a 
more flexible approach and a better estimate of treatment effects. Using the 
results of our already published network meta-analysis, our objective is to focus 
on the use of parametric survival curves to estimate progression free survival 
(PFS) in patients with chronic lymphocytic leukemia. METHODS: We tested 
parametric Weibull and log-logistic regression models with a two-parameter 
relative treatment effect (scale and shape), to indirectly compare PFS from 
multiple trials. We scanned survival curves from each included study, and used 
data from each consecutive interval to calculate model parameters. We 
estimated the number of deaths using the binomial likelihood distribution. We 
conducted the network meta-analysis using Bayesian statistical methods. We fit 
fixed and random effects models, and modeled scale and shape parameters on 
the log hazard scale. We evaluated goodness-of-fit by visually inspecting the 
linearity of diagnostic plots and comparing deviance information criteria (DIC). 
Using parameter estimates from the posterior summary we derived hazard rates, 
hazard ratios (HRs) and PFS survival curves for each treatment. To estimate the 
mean duration of PFS for each treatment, we calculated the area under each PFS 
curve. RESULTS: Seven randomized controlled trials of five treatments were 
included. The fixed effects Weibull model was the best fit for the data, with 
stronger linearity in the diagnostic plots and a lower DIC value. Hazard rates, 
HRs, PFS, survival, and median survival, with 95% credible intervals, were 
calculated for each treatment. Results suggest the hazard of disease progression 
for two treatments was constant, and increased over time for the other three. 
CONCLUSIONS: Parametric survival methods are useful in comparing PFS in the 
oncology setting.  
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APPLICATION OF RECLASSIFICATION MEASURES IN COMPARING RISK 
ADJUSTMENT MODELS  
Mehta HB, Mehta V, Girman CJ 
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OBJECTIVES: A traditional statistical measure such as concordance(c) statistics 
has been used widely for comparison of risk adjustment models; however, c-
statistic has been criticized for its insensitivity. To overcome the limitations of c-
statistics, novel reclassification measures (reclassification calibration statistics, 
Net Reclassification Index (NRI) and Integrated Discrimination Index (IDI)) have 
recently been proposed. The objective was to compare Charlson Comorbidity 
Index (CCI), Chronic Disease Score (CDS) and CCI+CDS in predicting one year 
mortality in type-2 diabetes mellitus patients (T2DM) by applying novel 
reclassification measures. METHODS: The Clinical Practice Research Database, 
electronic medical record data from UK, was used for this retrospective 
longitudinal cohort study. Patients diagnosed with T2DM from January 1, 2006 to 
December 31, 2006 were included. Diagnosis and prescription information upto 
1-year prior to the index date, i.e. first date of T2DM diagnosis, was used to 
create CCI and CDS, respectively. Patients were followed for 1 year from the 
index date to observe mortality. Descriptive statistics was used to describe the 
study cohort. In addition to traditional c-statistics from logistics regression, NRI 
and IDI were used to compare risk adjustment models. RESULTS: The cohort 
consisted of 26,191 patients with T2DM. The mean CCI and CDS were 0.24±0.67 
and 1.58±1.06, respectively. The c-statistics values for CCI, CDS and CCI+CDS 
models were 0.791 (95%CI: 0.777-0.805), 0.788 (95%CI: 0.774-0.802) and 0.803 
(95%CI: 0.789-0.817), respectively. The CDS and CCI+CDS reclassified 1.92% 
(p=0.238) and 6.50% (p=<0.001) patients into correct strata compared to the  
CCI. The IDI values for CDS and CCI+CDS were -0.64% (p=<0.001) and 0.43 
(p=<0.001). This means that addition of CDS in CCI improved the prediction of 
mortality. CONCLUSIONS: Combined score (CCI + CDS) performed better than 
individual scores. In addition to c-statistics, reclassification measures such as 




MATCHING-ADJUSTED INDIRECT COMPARISONS: A SIMULATION STUDY OF 
STATISTICAL PERFORMANCE  
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OBJECTIVES: When indirectly comparing treatments across separate clinical 
trials, matching-adjusted indirect comparisons (MAICs) can help avoid bias due 
to cross-trial differences in baseline characteristics. The approach uses 
propensity scores to adjust individual patient data from trials of one treatment 
to match published baseline characteristics from trials of comparator 
treatments. We assessed the statistical properties of MAIC, including the 
accuracy of estimated treatment effects and their standard errors, in a 
simulation study. METHODS: Each simulation scenario included two randomized 
controlled trials with a common control arm and a dichotomous outcome. 
Sample sizes ranged from 125 to 1000 patients per arm. Cross-trial differences in 
baseline characteristics were simulated to generate low, moderate and high 
levels of potential bias. For each simulated dataset, MAIC was used to estimate 
the relative treatment effect using individual patient data from one trial and 
aggregate data from the other. Estimated treatment effects and standard errors 
were evaluated for accuracy across 1000 simulations. Indirect comparisons 
without matching adjustment were evaluated in parallel. RESULTS: By design, 
indirect comparisons without matching exhibited biases ranging from 10% to 
200% of the true treatment effect across simulation scenarios. In contrast, the 
MAIC estimators exhibited negligible bias, falling within +/- 2% of the true 
treatment effect when all confounding variables were considered. The sandwich 
estimator closely approximated the true standard errors, and was slightly 
conservative, overestimating by as much as 8%, but usually less than 5%. These 
findings were consistent across the range of investigated sample sizes and levels 
of confounding. CONCLUSIONS: MAIC can remove bias due to observed cross-
trial differences and provide reliable assessments of statistical uncertainty for 
indirect comparisons that combine individual patient data and aggregate data.  
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BAYESIAN MODELS WITH A WEAKLY INFORMATIVE PRIOR: A USEFUL 
ALTERNATIVE FOR SOLVING SPARSE DATA PROBLEMS  
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OBJECTIVES: Separation problems (perfect prediction of a binary outcome by one 
or more covariates) are common in health outcomes research in high prevalence, 
